Open Orphan Share Discussion Threads

[pogue] 03/2/2021 19:24

Well clues for what is next
Immune Modulator is going to be monetized soon with divi in specie first of the 3 assets we are selling.
Wearables worth as much as ORPH just now will probably launch as a separate company called Disease in Motion
4th facility will be in London in 100 bed hotel nearby will be for non covid challenge studies as will the new clinic in the Whitechapel hotel announced today.

[m5] 03/2/2021 19:22

Great presentation. All very very positive. Invesco is the reason the share price had stalled. Once they have gone off we will jolly well go. Very exciting year ahead. Very pleased with that. Does not really get much better.

[jeanesy] 03/2/2021 19:21

CF is the man :)

[molatovkid] 03/2/2021 19:20

Brilliant presentation !

Sounds like a 100 bed unit coming.

[discojames] 03/2/2021 19:17

"all non core assets will monetise"

[pierre oreilly] 03/2/2021 18:46

Well good luck with the disruptive kettles. Do you like the ambulance chaser too? Think I'll stick with challenge studies and furthermore not log in to these things until it's orph's time!

[extrader] 03/2/2021 18:26

Hi Pierre Oreilly,

Studies, kettles, challenge ?

The man behind STRIX, John C Taylor, used some of his wealth to fund this critter :

hxxps://www.johnctaylor.com/the-chronophage/

ATB

[pierre oreilly] 03/2/2021 18:11

Kettles or challenge studies?

[extrader] 03/2/2021 17:45

Hi 1gw,

Other Codagenix plus points he mentioned :

- backer is Jim Simons ,Euclidean Capital, the founder of Renaissance Capital *;

- Merck and Novartis are keen to push Codagenix as a 'next generation' coronavirus vaccine, because they missed out on round 1...

ATB

*.."A viral gene design algorithm that is unlike any first-generation vaccine platforms
Codagenix developed a viral gene customization algorithm that is unlike any first-generation vaccine platforms. We do not use an attenuated backbone virus carrying an antigen, virus-like particles (VLPs), or mRNAs expressing a single antigen. Those iterations of vaccine platforms are just that, “platforms,221; or physical entities of some kind to which you can attach only 1 or 2 target antigens. Codagenix’s unique approach targets the Achilles heel of all viruses. In fact, The New England Journal of Medicine theorized that our approach could be applied to “any virus”. (Coffin 2008)

How our platform works
Every virus, whether it is influenza, zika, or the common cold, uses the host cell machinery (ribosome) to translate its genome and synthesize its proteins – how the genome is read by the ribosome is our algorithm’s point of attack/attenuation . The Codagenix computer algorithm re-codes and “deoptimizes” the codon pair bias/codon bias of viral genes – putting the genes in a language that is read slowly by the host cell ribosome. These deoptimized genes encode the same exact protein sequences as the wildtype but do so in a suboptimal fashion. Deoptimization results in a vast reduction of pathogenesis, yet induction of a potent immune response given the presentation of all perfectly matched antigens of the wild type virus, yielding a potent vaccine. Codagenix deoptimzed viruses are ideal for use as live-attenuated vaccines and given the re-coding and atypical RNA, robust oncolytics for solid tumors.

[pierre oreilly] 03/2/2021 17:13

close today 25.5 - Bingo!

1st 30 mins tomorrow 27,5p - tba

close tomrrow 26.5p. - tba

Just a bit of fun, i don't usually like the guess the (short term) price game. Tempted to up tomorrow's close by 0.5p

[1gw] 03/2/2021 17:05

So I think he is implying that Codagenix are the major client which has got the 2nd facility off the ground. And it sounds to me rather like they might have an option on 2H capacity for their Phase 2 challenge trial.

[lako42] 03/2/2021 17:03

Massive positive that I hadn't thought of


He's had the vaccine :)

[1gw] 03/2/2021 17:01

That Yahoo! Finance video is also good. On the new facility, I heard him as hoping that a Codagenix Phase 2 Challenge trial will occupy it in the summer.

He also talks about covid challenge studies in general. He confirms that he is still waiting for regulatory approval but thinks that will come. And:

"As soon as we get regulatory approval we could fill it 10 times over"

[owenski] 03/2/2021 16:57

reminder -

[lfdkmp] 03/2/2021 16:49

How are your end of day candlesticks, m5? :-)

[m5] 03/2/2021 16:47

Watch tonight fella, that was just a taster! 😁

[trader_3] 03/2/2021 16:46

Cathal Friel - Yahoo Finance Video

[2350220] 03/2/2021 16:45

Wow m5, what a flippin interview!!
Just a shame that I can't add anymore to my Spreadex long positions, as they've got Open Orphan and 4D Pharma as close only. ie they're not accepting any new positions 😔
Anyway, I'm very happy that I've at least got some exposure here.
John

[m5] 03/2/2021 16:28

1gw3 Feb '21 - 16:09 - 11379 of 11380

That will do me, no need for anymore. 👍👍

[bearnecessities] 03/2/2021 16:19

Same here. Nice to hear that he's obviously listened to shareholders and changed his stance/wording on it.Guess we can now put that subject to bed, although I'm perplexed by the share price action today on that news like most of us are.

[1gw] 03/2/2021 16:09

Thanks m5.

As I heard it, he limited himself to:

"We want to keep growing the shareprice"

[m5] 03/2/2021 15:55

CF on todays RNS.

[wassapper] 03/2/2021 14:46

Moving on. Some kind soul posted this a few weeks' ago. I've only just got round to reading it but it does show where we might be, and also where we are not, with regard to Covid CHIMS. Bascially, it won't happen tomorrow.

[wassapper] 03/2/2021 14:44

JH - sorry I don't know what you mean. Only closing bets for ORPH, and their "story" for not taking opening bets is as I have stated. This was reiterated quite recently when I enquired about another stock.